RIPK1 inhibitors such as GSK2982772 and GSK3145095 are currently evaluated in several clinical trials in rheumatoid arthritis (NCT02858492), psoriasis (NCT02776033), ulcerative colitis (NCT02903966) and cancer (NCT03681951) (Clinicaltrials.gov). This evidence concerns the gene RIPK1 and cancer.